Melanoma-associated antigen A10-specific T-cells - Adaptimmune

Drug Profile

Melanoma-associated antigen A10-specific T-cells - Adaptimmune

Alternative Names: MAGE A-10 TCR; MAGE A10-specific T-cells - Adaptimmune; MAGE A10-transduced lymphocytes; MAGE-A10 SPEAR T-cell therapy; MAGE-A10c796T

Latest Information Update: 20 Jul 2018

Price : *
* Final gross price and currency may vary according to local VAT and billing address.
* Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase. A link to download a PDF version of the drug profile will be included in your email receipt. Adis is an information provider. We do not sell or distribute the pharmaceutical compounds written about in this database.

At a glance

  • Originator Adaptimmune
  • Developer Adaptimmune; University of Texas M. D. Anderson Cancer Center
  • Class Gene therapies; Immunotherapies; T lymphocyte cell therapies
  • Mechanism of Action Immunologic cytotoxicity; T lymphocyte replacements
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity No

Highest Development Phases

  • Phase I/II Non-small cell lung cancer
  • Phase I Bladder cancer; Head and neck cancer; Malignant melanoma; Urogenital cancer
  • Clinical Phase Unknown Haematological malignancies; Solid tumours

Most Recent Events

  • 18 Jul 2018 Safety Review Committee recommends dose escalation to third dose cohorts in ADP 0022-003 and Triple tumour studies
  • 01 Jun 2018 Pooled analysis of adverse events data from a phase I trial in Urothelial, Melanoma, Head and neck and Non-small cell lung cancer and a phase II trial in Non-small cell lung cancer presented at the 54th Annual Meeting of the American Society of Clinical Oncology (ASCO-2018)
  • 28 Feb 2018 Clinical trials in Haematological malignancies in Canada, USA (Parenteral) (NCT03391791)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at so we can help.

Back to top